In spite of a high variability within groups for the tested tau antibodies (Supplementary Figs. S3, S4), we observed a significant upregulation of phosphorylated tau species (apart from pT181), as well as enrichment of some P1/2 regions and C-terminal epitopes in both the MTG and AMY crude tissue homogenates in AD cases with and without concomitant aSyn pathology when compared to PDD and control cases. Here, MAPT is linked to Alzheimer disease.